CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing AntibodyFragment-based Therapeutics for Geographic AtrophyAugust 2, 2023 11:00 am
Zürich, Switzerland, August 2, 2023 – CDR-Life Inc. today announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021.
GA is a progressive, irreversible retinal disease and one of the leading causes of blindness in people over 65 years of age. It occurs in people living with age-related macular degeneration (AMD) and affects approximately eight million people globally.
“This milestone is continued validation of the expertise of our team to identify high quality antibody fragment-based drug candidates across a broad range of therapeutic applications,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “Our partnership with Boehringer Ingelheim has proven successful and will hopefully bring life changing new treatments for people living with this devastating disease.”
In addition to partnering with Boehringer Ingelheim, CDR-Life is building its own pipeline of novel antibody fragment-based T cell engagers against solid tumors. By uniquely targeting the major histocompatibility complex (MHC), CDR-Life is able to access a new class of intracellular tumor antigens to engage T cells. The company’s first of several therapeutic candidates in development, CDR404, targets MAGE-A4 and is anticipated to enter the clinic in 2024.
CDR-Life is developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). Our versatile MHC-targeted antibody platform increases access to a vast array of antigens that were not previously addressable, to develop a pipeline of first in class therapeutics across a broad range of solid tumors. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to redirect and activate the patient’s own immune system to eliminate their tumors.
This post was written by cdr_admin